Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 2/20 | 0.46 |
| ▸ | AURKA | O14965 | 1/20 | 0.42 |
| ▸ | HTR2C | P28335 | 1/20 | 0.42 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.42 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.41 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.41 |
| ▸ | ABL1 | P00519 | 1/20 | 0.41 |
| ▸ | BCR | P11274 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30114879 | 1.00 | BCHE (0.46) | BCHEAURKAHTR2CMCHR1CSNK1D | |
| SCHEMBL20188166 | 0.92 | AURKA (0.44) | AURKAABL1 | |
| SCHEMBL30530307 | 0.92 | AURKA (0.44) | AURKAABL1 | |
| SCHEMBL30530317 | 0.91 | BCHE (0.45) | BCHEHTR2CMCHR1CSNK1DCSNK1E | |
| SCHEMBL20188373 | 0.91 | BCHE (0.45) | BCHEHTR2CMCHR1CSNK1DCSNK1E | |
| SCHEMBL30114852 | 0.88 | BCHE (0.44) | BCHEAURKAHTR2CMCHR1 | |
| SCHEMBL20187754 | 0.88 | BCHE (0.44) | BCHEAURKAHTR2CMCHR1 | |
| SCHEMBL20190260 | 0.86 | AURKA (0.48) | AURKAABL1BCR | |
| SCHEMBL21799066 | 0.85 | ABL1 (0.54) | HTR2CMCHR1ABL1BCR | |
| SCHEMBL30530294 | 0.85 | ABL1 (0.54) | HTR2CMCHR1ABL1BCR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3544685-B1 | HETROARYLAMINE COMPOUNDS FOR MODULATING THE HEDGEHOG PATHWAY AND PREPARING METHOD AND USES THEREOF | DEV CT BIOTECHNOLOGY (TW) | 2023-01-04 | — | — | EP | claimed |
| US-10793542-B2 | Hetroarylamine compounds for modulating the hedgehog pathway and preparing method and uses thereof | DEVELOPMENT CENTER FOR BIOTECHNOLOGY (TW) | 2020-10-06 | — | — | US | claimed |
| US-20200079753-A1 | HETROARYLAMINE COMPOUNDS FOR MODULATING THE HEDGEHOG PATHWAY AND PREPARING METHOD AND USES THEREOF | DEVELOPMENT CENTER FOR BIOTECHNOLOGY (TW) | 2020-03-12 | — | — | US | claimed |
| EP-3544685-A1 | HETROARYLAMINE COMPOUNDS FOR MODULATING THE HEDGEHOG PATHWAY AND PREPARING METHOD AND USES THEREOF | Development Center for Biotechnology (TW) | 2019-10-02 | — | — | EP | claimed |
| WO-2018098250-A1 | HETROARYLAMINE COMPOUNDS FOR MODULATING THE HEDGEHOG PATHWAY AND PREPARING METHOD AND USES THEREOF | DEVELOPMENT CENTER FOR BIOTECHNOLOGY (TW) | 2018-05-31 | — | — | WO | claimed |
| EP-3544685-B1 | HETROARYLAMINE COMPOUNDS FOR MODULATING THE HEDGEHOG PATHWAY AND PREPARING METHOD AND USES THEREOF | DEV CT BIOTECHNOLOGY (TW) | 2023-01-04 | — | — | EP | disclosed |
| US-10793542-B2 | Hetroarylamine compounds for modulating the hedgehog pathway and preparing method and uses thereof | DEVELOPMENT CENTER FOR BIOTECHNOLOGY (TW) | 2020-10-06 | — | — | US | disclosed |
| US-10793542-B2 | Hetroarylamine compounds for modulating the hedgehog pathway and preparing method and uses thereof | DEVELOPMENT CENTER FOR BIOTECHNOLOGY (TW) | 2020-10-06 | — | — | US | disclosed |
| US-20200079753-A1 | HETROARYLAMINE COMPOUNDS FOR MODULATING THE HEDGEHOG PATHWAY AND PREPARING METHOD AND USES THEREOF | DEVELOPMENT CENTER FOR BIOTECHNOLOGY (TW) | 2020-03-12 | — | — | US | disclosed |
| EP-3544685-A1 | HETROARYLAMINE COMPOUNDS FOR MODULATING THE HEDGEHOG PATHWAY AND PREPARING METHOD AND USES THEREOF | Development Center for Biotechnology (TW) | 2019-10-02 | — | — | EP | disclosed |
| WO-2018098250-A1 | HETROARYLAMINE COMPOUNDS FOR MODULATING THE HEDGEHOG PATHWAY AND PREPARING METHOD AND USES THEREOF | DEVELOPMENT CENTER FOR BIOTECHNOLOGY (TW) | 2018-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200079753-A1 | HETROARYLAMINE COMPOUNDS FOR MODULATING THE HEDGEHOG PATHWAY AND PREPARING METHOD AND USES THEREOF | SHH, GLI1, SMO | BCHE 164/4885AURKA 3493/4885HTR2C 206/4885 |
| US-10793542-B2 | Hetroarylamine compounds for modulating the hedgehog pathway and preparing method and uses thereof | SHH, GLI1, NR1H4 | BCHE 47/4885AURKA 3336/4885HTR2C 322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.